The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years.

Evidence demonstrates that waning of protection against the Omicron variant occurs after a two-dose primary vaccination schedule and a booster dose is required to increase protection against infection and severe disease.

This statement addresses the safety, efficacy and epidemiological considerations.

Follow the link below to read the recommendations in full:
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years.

MVEC acknowledges the traditional owners of the lands on which we live, work and educate. We pay our respects to their Elders, past, present and emerging.
We are committed to honouring Australian Aboriginal and Torres Strait Islander peoples’ unique cultural and spiritual relationships to the land, waters and seas.

关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。

分享这个